Immunoassay IVD (In Vitro Diagnostic) Market in China 2021
The immunoassay IVD (in vitro diagnostic) market in China in terms of revenue is set to grow by US$ 12 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 20.1% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for immunoassay IVD (in vitro diagnostic). The China immunoassay IVD (in vitro diagnostic) market is segmented on the basis of brand. By brand, it is categorized into domestic brand, and multinational brand. The multinational brand segment held the largest market share in 2020. Moreover, it is expected to witness the highest CAGR during the forecast period.
The report has profiled some of the key players of the market such as Abbott Laboratories International Co., Danaher Corporation, Roche Holding AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Siemens AG, Sysmex Corporation.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the immunoassay IVD (in vitro diagnostic) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Brand: domestic brand, and multinational brand
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China immunoassay IVD (in vitro diagnostic) market
Pinpoint growth sectors and trends for investment
Understand what the future of the immunoassay IVD (in vitro diagnostic) market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for immunoassay IVD (in vitro diagnostic). The China immunoassay IVD (in vitro diagnostic) market is segmented on the basis of brand. By brand, it is categorized into domestic brand, and multinational brand. The multinational brand segment held the largest market share in 2020. Moreover, it is expected to witness the highest CAGR during the forecast period.
The report has profiled some of the key players of the market such as Abbott Laboratories International Co., Danaher Corporation, Roche Holding AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Siemens AG, Sysmex Corporation.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the immunoassay IVD (in vitro diagnostic) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Brand: domestic brand, and multinational brand
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China immunoassay IVD (in vitro diagnostic) market
Pinpoint growth sectors and trends for investment
Understand what the future of the immunoassay IVD (in vitro diagnostic) market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. IMMUNOASSAY IVD (IN VITRO DIAGNOSTIC) MARKET BY BRAND
4.1 Domestic Brand
4.2 Multinational Brand
5. COMPANY PROFILES
5.1 Abbott Laboratories International Co.
5.2 Danaher Corporation
5.3 Roche Holding AG
5.4 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
5.5 Siemens AG
5.6 Sysmex Corporation
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. IMMUNOASSAY IVD (IN VITRO DIAGNOSTIC) MARKET BY BRAND
4.1 Domestic Brand
4.2 Multinational Brand
5. COMPANY PROFILES
5.1 Abbott Laboratories International Co.
5.2 Danaher Corporation
5.3 Roche Holding AG
5.4 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
5.5 Siemens AG
5.6 Sysmex Corporation
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
